dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Zandberg, Dan P. |
dc.contributor.author | Algazi, Alain P. |
dc.contributor.author | Jimeno, Antonio |
dc.contributor.author | Good, James S. |
dc.contributor.author | Fayette, Jérôme |
dc.contributor.author | Bouganim, Nathaniel |
dc.contributor.author | Braña Garcia, Irene |
dc.date.accessioned | 2021-03-16T09:47:01Z |
dc.date.available | 2021-03-16T09:47:01Z |
dc.date.issued | 2019-01 |
dc.identifier.citation | Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 2019 Jan;107:142–52. |
dc.identifier.issn | 0959-8049 |
dc.identifier.uri | https://hdl.handle.net/11351/5761 |
dc.description | Anticossos; Immunoteràpia; Càncer de cap i coll |
dc.description.sponsorship | This study was supported by AstraZeneca. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | European Journal of Cancer;107 |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Cap - Càncer |
dc.subject | Coll - Càncer |
dc.subject | Anticossos monoclonals |
dc.subject.mesh | Head and Neck Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antibodies, Monoclonal |
dc.subject.mesh | Squamous Cell Carcinoma of Head and Neck |
dc.title | Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.ejca.2018.11.015 |
dc.subject.decs | neoplasias de cabeza y cuello |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | anticuerpos monoclonales |
dc.subject.decs | carcinoma de células escamosas de cabeza y cuello |
dc.relation.publishversion | https://www.ejcancer.com/article/S0959-8049(18)31513-2/fulltext |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Zandberg DP] University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA, USA. [Algazi AP] University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. [Jimeno A] Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO, USA. [Good JS] Institute of Head and Neck Studies and Education, Queen Elizabeth Hospital, Birmingham, UK. [Fayette J] Clinical Oncology, Cancer Center Centre Léon Bérard, University of Lyon, Lyon, France. [Bouganim N] Department of Oncology, McGill University Health Centre, Montreal, QC, Canada. [Braña I] Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain |
dc.identifier.pmid | 30576970 |
dc.identifier.wos | 000454908700018 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |